|
SALIMED: Targeted Salix crossing and chemoprofiling for improved medicinal potential of willow bark
Projektbeschreibung:
With increasing life expectancy and growth of the elderly population, an alarming escalation of age-related chronic, inflammatory disease conditions are noted demanding new
treatments and preventive approaches. The therapeutic and health-promoting effects of willow (salix spp.) bark preparations, especially against inflammatory diseases and pain conditions in humans, are known, however the correlation of therapeutic effects to certain
individual bioactive small molecules or their complex mixtures is still lacking consequently impairing product optimization. To date, willow bark has mainly been evaluated according to its salicin content. Further, plant breeding programs and deforestation of Salix species
focused on biomass production as renewable sources for energy use. Usually whole Salix
shoots are then used for bioenergy purposes, which results in an unclean combustion due to the bark.
Objective of the project is to identify suitable willow clones which exhibit high phytochemical levels with best medicinal effects to use as phytopharmaceutical and which also show a high biomass production and rust resistance. Extracts from these willow barks should achieve specific therapeutic benefits with few undesirable side effects and should be suitable to extend standard medications such as Aspirin™ in the treatment of inflammation related diseases.
Projektlaufzeit:
Projektbeginn: 01.07.2017 Projektende: 30.06.2020
Projektleitung:
Lamy E
Albert-Ludwigs-Universität Freiburg
Institut für Infektionsprävention und Krankenhaushygiene
Breisacher Str. 115 B 79106 Freiburg
Telefon: 0761-270-82060 Fax: 0761-270-82030
http://www.uniklinik-freiburg.de/iuk/live/index.html
Finanzierung:
Aktueller Forschungsbericht
|